Acquisition - March 26, 2014
AstraZeneca completes Japanese acquisition
AstraZeneca completes purchase of Sumitomo Chemical’s stake in AstraZeneca K.K. The company announced on March 26 that it has completed the purchase of Sumitomo Chemical’s remaining shares in AstraZeneca K.K. According to a statement the purchase was valued at approximately JPY10 billion ($102 million). This gives AstraZeneca control of the entire shareholding of AstraZeneca K.K. “Our […]
Collaboration - March 25, 2014
Neurovive collaborates with A1M Pharma
NeuroVive Pharmaceutical AB and A1M Pharma AB have announced that the two companies are initiating a research collaboration in mitochondrial medicine. Initially, the purpose of the collaboration is to utilize the companies’ complementary scientific platforms within the framework of ongoing research projects. The companies will evaluate results achieved to date, then explore the potential for […]
Drug Development Pharma - March 25, 2014
Russian yes to simeprevir
The Russian Ministry of Health has approved Sovriad (simeprevir) for the treatment of chronic hepatitis C genotype 1 infection, announces Medivir. Russia will be the first country within EMEA to gain access to simeprevir. “The Russian approval is another important event for simeprevir and provides the hepatitis C patients in Russia with a new HCV treatment” […]
Intellectual Property - March 25, 2014
Moberg Pharma launches new patent formulation
The company will start shipping a new patent pending formulation of Kerasal Nail to customers in the US. According to Moberg Pharma the new product is shipped as a flow-through. It will be available at all existing retailers, including major drugstores CVS, Walgreens and Rite-Aid, mass retailers such as Walmart and Target as well as […]
Drug Development Pharma - March 24, 2014
Simeprevir receives positive CHMP opinion
The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending Marketing Authorisation in the European Union for the use of simeprevir in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult patients. “The recommendation is one additional step in the global strategy that our […]
Drug Development Pharma - March 24, 2014
Sobi’s Alprolix gets approval in Canada
Health Canada has approved the company’s treatment for the control and prevention of bleeding episodes and routine prophylaxis. Alprolix has been approved for the treatment of adults and children aged 12 and older, with haemophilia B. This is the first regulatory approval worldwide for Alprolix, which is currently under review by regulatory authorities in several other countries, including […]
